ArticleJCEM case reports2025
A Call for Use of Lipid Fractionation Studies in Patients With Abnormal Standard Lipid Profiles.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 54-year-old female individual with a history of hyperlipidemia, hypothyroidism, latent autoimmune diabetes of the adult (LADA) with hypoglycemia unawareness, vitiligo, and asthma presented with exercise-limiting pleuritic chest pain and dyspnea. She underwent a full pulmonary and cardiac workup locally and at Mayo Clinic, which were normal and negative for pulmonary embolism and showed no evidence of cardiac ischemia. Her family history and abnormal lipid panels suggested possible familial hypercholesterolemia by Dutch criteria. Lipid fractionation studies were done to further assess abnormal lipid levels and symptoms, as she lives a generally healthy and active lifestyle. Lipid fractionation studies revealed abnormal small, dense (sdLDL) and low-density lipoproteins (LDL) particle numbers. She was started on a triple cholesterol management regimen of ezetimibe, evolocumab, and bempedoic acid, which improved lipid fractionation values and symptoms. This case highlights the utility of using lipid fractionation studies in addition to traditional lipid panels to best treat patients with abnormal lipid panels on lipid-lowering therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.